Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 118-125

  Liu, Zuqiang ^a   Falo Jr , Louis D ^a,b   You, Zhaoyang ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CD8+ T LYMPHOCYTE; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE SILENCING; IMMUNOMODULATION; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-10; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 79960387864     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003378     Document Type: Article

References (44)

1. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
2. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
3. + regulatory T cell proliferation. J. Exp. Med. 202: 919-929.
4. + T regulatory cells: role of tumor-derived TGF-β. J. Immunol. 178: 2883-2892.
5. Sharma, M. D., B. Baban, P. Chandler, D.-Y. Hou, N. Singh, H. Yagita, M. Azuma, B. R. Blazar, A. L. Mellor, and D. H. Munn. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117: 2570-2582.
6. Pan, P.-Y., G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S.-H. Chen. 2008. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111: 219-228.
7. Curiel, T. J. 2008. Regulatory T cells and treatment of cancer. Curr. Opin. Immunol. 20: 241-246.
8. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
9. Olkhanud, P. B., B. Damdinsuren, M. Bodogai, R. E. Gress, R. Sen, K. Wejksza, E. Malchinkhuu, R. P. Wersto, and A. Biragyn. 2011. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T regulatory cells. Cancer Res. DOI: 10.1158/0008-5472.CAN-10-4316.
10. Mocellin, S., F. M. Marincola, and H. A. Young. 2005. Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 78: 1043-1051.
11. O'Garra, A., F. J. Barrat, A. G. Castro, A. Vicari, and C. Hawrylowicz. 2008. Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 223: 114-131.
12. Mosser, D. M., and X. Zhang. 2008. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226: 205-218.
13. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212: 28-50.
14. Saraiva, M., and A. O'Garra. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10: 170-181.
15. Larmonier, N., M. Marron, Y. Zeng, J. Cantrell, A. Romanoski, M. Sepassi, S. Thompson, X. Chen, S. Andreansky, and E. Katsanis. 2007. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol. Immunother. 56: 48-59.
16. Strauss, L., C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson, and T. L. Whiteside. 2007. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13: 4345-4354.
17. + regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244.
18. Rovere-Querini, P., A. Capobianco, P. Scaffidi, B. Valentinis, F. Catalanotti, M. Giazzon, I. E. Dumitriu, S. Müller, M. Iannacone, C. Traversari, et al. 2004. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5: 825-830. (Pubitemid 39199174)
19. Yang, H., H. Wang, C. J. Czura, and K. J. Tracey. 2005. The cytokine activity of HMGB1. J. Leukoc. Biol. 78: 1-8.
20. Dumitriu, I. E., P. Baruah, A. A. Manfredi, M. E. Bianchi, and P. Rovere-Querini. 2005. HMGB1: guiding immunity from within. Trends Immunol. 26: 381-387. (Pubitemid 40835844)
21. Bianchi, M. E., and A. A. Manfredi. 2007. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220: 35-46.
22. Tang, D., R. Kang, K. M. Livesey, C. W. Cheh, A. Farkas, P. Loughran, G. Hoppe, M. E. Bianchi, K. J. Tracey, H. J. Zeh, III, and M. T. Lotze. 2010. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190: 881-892.
23. Ellerman, J. E., C. K. Brown, M. de Vera, H. J. Zeh, T. Billiar, A. Rubartelli, and M. T. Lotze. 2007. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res. 13: 2836-2848.
24. Campana, L., L. Bosurgi, and P. Rovere-Querini. 2008. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr. Opin. Immunol. 20: 518-523.
25. Srikrishna, G., and H. H. Freeze. 2009. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11: 615-628.
26. Sims, G. P., D. C. Rowe, S. T. Rietdijk, R. Herbst, and A. J. Coyle. 2010. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28: 367-388.
27. Tang, D., R. Kang, H. J. Zeh, III, and M. T. Lotze. 2010. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 1799: 131-140.
28. Rojas, A., H. Figueroa, and E. Morales. 2010. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 31: 334-341.
29. Apetoh, L., F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G. Mignot, M. C. Maiuri, E. Ullrich, P. Saulnier, et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13: 1050-1059.
30. Curtin, J. F., N. Liu, M. Candolfi, W. Xiong, H. Assi, K. Yagiz, M. R. Edwards, K. S. Michelsen, K. M. Kroeger, C. Liu, et al. 2009. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6: e10.
31. Guerriero, J. L., D. Ditsworth, J. M. Catanzaro, G. Sabino, M. B. Furie, R. R. Kew, H. C. Crawford, and W.-X. Zong. 2011. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J. Immunol. 186: 3517-3526.
32. Kusume, A., T. Sasahira, Y. Luo, M. Isobe, N. Nakagawa, N. Tatsumoto, K. Fujii, H. Ohmori, and H. Kuniyasu. 2009. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76: 155-162.
33. Kim, J. H., N. Majumder, H. Lin, J. Chen, L. D. Falo, Jr., and Z. You. 2005. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer. Mol. Ther. 11: 941-949.
34. Liu, Z., J. H. Kim, L. D. Falo, Jr., and Z. You. 2009. Tumor regulatory T cells potently abrogate antitumor immunity. J. Immunol. 182: 6160-6167.
35. Liu, Z., H. S. Noh, J. Chen, J. H. Kim, L. D. Falo, Jr., and Z. You. 2008. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J. Immunol. 181: 4363-4370.
36. Hagenbaugh, A., S. Sharma, S. M. Dubinett, S. H.-Y. Wei, R. Aranda, H. Cheroutre, D. J. Fowell, S. Binder, B. Tsao, R. M. Locksley, et al. 1997. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185: 2101-2110.
37. Sharma, S., M. Stolina, Y. Lin, B. Gardner, P. W. Miller, M. Kronenberg, and S. M. Dubinett. 1999. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 163: 5020-5028.
38. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
39. Gdynia, G., M. Keith, J. Kopitz, M. Bergmann, A. Fassl, A. N. R. Weber, J. George, T. Kees, H.-W. Zentgraf, O. D. Wiestler, et al. 2010. Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria. Cancer Res. 70: 8558-8568.
40. Shevach, E. M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.
41. Huang, L. F., Y. M. Yao, L. T. Zhang, N. Dong, Y. Yu, and Z. Y. Sheng. 2009. The effect of high-mobility group box 1 protein on activity of regulatory T cells after thermal injury in rats. Shock 31: 322-329.
42. Gnanasekar, M., S. Thirugnanam, and K. Ramaswamy. 2009. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int. J. Oncol. 34: 425-431.
43. Kazama, H., J. E. Ricci, J. M. Herndon, G. Hoppe, D. R. Green, and T. A. Ferguson. 2008. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29: 21-32.
44. Taguchi, A., D. C. Blood, G. del Toro, A. Canet, D. C. Lee, W. Qu, N. Tanji, Y. Lu, E. Lalla, C. Fu, et al. 2000. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360. (Pubitemid 30337069)